SUMMIT, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Celgene Corporation , announced that as a result of the decision by Standard and Poor’s Corporation to include Celgene Corporation in the S&P 500 Index, the Company intends to issue up to approximately 20 million shares of its common stock.
The purpose of the offering is to partially meet the anticipated demand of index funds to purchase Celgene common stock when the Company is added to the S&P 500 Index, currently contemplated at the close of business on Friday, November 3, 2006. Proceeds from the offering will be used for general corporate purposes, including working capital, capital expenditures, possible future licenses, strategic investments and acquisitions.
The Company intends to offer the shares in an underwritten offering to be registered pursuant to the Securities Act of 1933, as amended. This news release does not constitute an offer of any securities for sale. Please direct all inquires to the corporate communications department of Celgene Corporation at 908-673-9530.
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company’s control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company’s filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.
Celgene Corporation
CONTACT: Robert J. Hugin, President and COO, +1-908-673-9102, or Brian P.Gill, Senior Director PR/IR, +1-908-673-9530, both for Celgene Corporation
Web site: http://www.celgene.com/
